+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Infliximab therapy for Crohns disease The Crohns and colitis center of New Jersey experience



Infliximab therapy for Crohns disease The Crohns and colitis center of New Jersey experience



Gastroenterology 118(4 Suppl 2 Part 2): AGA A1334




(PDF emailed within 0-6 h: $19.90)

Accession: 035130737

Download citation: RISBibTeXText

DOI: 10.1016/S0016-5085(00)81203-2


Related references

The 10-year experience with purinethol at the Crohns and Colitis Center of New Jersey. Gastroenterology 120(5 Supplement 1): A 623, 2001

Long term outcome of top-down therapy in Crohns disease: A single-center experience. Inflammatory Bowel Diseases 17: S49-S50, 2011

Infliximab for Crohns Disease One units experience. Gut 50(Supplement 2): A76, 2002

Assessment of infliximab utilization for Crohns disease and Ulcerative Colitis patients across different sites-of-care. Inflammatory Bowel Diseases 17: S38-S39, 2011

Infliximab for Crohns Disease: More Than 13 Years of Real-world Experience. Inflammatory Bowel Diseases 24(3): 490-501, 2018

Infliximab therapy for fistulizing Crohns disease. American Journal of Gastroenterology 95(9): 2635, 2000

Infliximab in Crohns disease An office-based gastroenterologists community experience. American Journal of Gastroenterology 95(9): 2495, 2000

Treatment of Crohns disease with infliximab An initial community practice experience. Gastroenterology 118(4 Suppl 2 Part 1): AGA A567, 2000

Crohns colitis with carcinoma and dysplasia a case and a review of 100 small and large bowel resections for crohns disease to detect incidence of dysplasia. American Journal of Surgical Pathology 7(2): 151-160, 1983

Preliminary clinical experience with Infliximab in the treatment of refractory and fistulizing Crohns disease. Gastroenterology 118(4 Suppl 2 Part 1): AGA A565, 2000

Collaborative experience of open-label infliximab in refractory pediatric Crohns disease. JPGN 31(Supplement 2): S227, 2000

Infliximab treatment for Crohns disease treated with elemental diet The Tokyo experience. American Journal of Gastroenterology 98(9 Supplement): S252-S253, 2003

Infliximab in clinical routine: experience with Crohns disease and biomarkers of inflammation over 5 years. European Journal of Gastroenterology & Hepatology 21(10): 1168-1176, 2009

Safety and efficacy of infliximab therapy in HIV patients with Crohns disease. Gastroenterology 122(4 Suppl 1): A 616, 2002

Endoscopic characteristics of the relapse of Crohns disease after infliximab therapy. Gastroenterology 118(4 Suppl 2 Part 1): AGA A568, 2000